Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealthSpring Glaucoma Shunt Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy SUR713.034

    Aqueous Shunts and Stents for Glaucoma

    Customize your policy alerts

    Sign up for healthspring Policy SUR713.034 alerts

    Get alerted when Policy SUR713.034 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers FDA-approved ab externo aqueous shunts and ab interno aqueous stents for glaucoma when medical therapy has failed to adequately control intraocular pressure; certain ab interno stents may be covered with cataract surgery for mild-to-moderate open-angle glaucoma.

    Policy Summary
    PayerHealthSpring
    PolicyAqueous Shunts and Stents for Glaucoma
    Policy CodePolicy SUR713.034
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionReview the written Medical Policy coverage position together with the member's benefit contract or Summary Plan Description before determining coverage.
    SourceLink
    POLICY UPDATE CHANGES

    This is a new medical document establishing coverage criteria for FDA-approved ab externo aqueous shunts and ab interno aqueous stents for glaucoma.

    2Aqueous device approaches addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 or 2
    FDA-approved stents permitted with cataract surgery
    Mild-to-moderateGlaucoma severity for stents with cataract surgery
    Mid-teensApproximate pressure reduction range
    ExperimentalNonqualifying uses

    Medical Necessity and Covered Indications

    Ab externo aqueous shunts

    Ab externo aqueous shunt insertion may be considered medically necessary when all criteria are met.

    Ab externo medical necessity

    • Required conditions: FDA-approved ab externo aqueous shuntFDA-approved
    • Required condition: Individual has glaucomaGlaucoma diagnosis
    • Required condition: Medical therapy has failed to adequately control intraocular pressureInadequately controlled intraocular pressure despite medical therapy

    Ab interno aqueous stents for inadequately controlled glaucoma

    Ab interno aqueous stent insertion may be considered medically necessary when all criteria are met.

    Ab interno medical necessity for inadequately controlled glaucoma

    • Required conditions: FDA-approved ab interno aqueous stentFDA-approved
    • Required condition: Individual has glaucomaGlaucoma diagnosis
    • Required condition: Medical therapy has failed to adequately control intraocular pressureInadequately controlled intraocular pressure despite medical therapy

    Ab interno stents with cataract surgery

    Implantation with cataract surgery may be considered medically necessary when all criteria are met.

    Ab interno stent with cataract surgery

    • Device and procedure: Implantation of 1 or 2 FDA-approved ab interno stents in conjunction with cataract surgery1 or 2 FDA-approved stents with cataract surgery
    • Permitted glaucoma severity

      • Mild open-angle glaucoma: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma and a normal visual field on standard automated perimetry.Normal visual field on SAP
      • Moderate open-angle glaucoma:

    Ab externo aqueous shunt

    May be considered medically necessary when all stated conditions are met.

    Ab externo aqueous shunt: Insertion of an FDA-approved ab externo aqueous shunt may be considered medically necessary as a method to reduce intraocular pressure in an individual with glaucoma when medical therapy has failed to adequately control intraocular pressure.Medical therapy has failed to adequately control intraocular pressure

    The device must be approved by the U.S. Food and Drug Administration.

    Ab interno aqueous stent after failed medical therapy

    May be considered medically necessary when all stated conditions are met.

    Ab interno aqueous stent after failed medical therapy: Insertion of an FDA-approved ab interno aqueous stent may be considered medically necessary as a method to reduce intraocular pressure in an individual with glaucoma when medical therapy has failed to adequately control intraocular pressure.Medical therapy has failed to adequately control intraocular pressure

    The device must be approved by the U.S. Food and Drug Administration.

    Ab interno stent with cataract surgery

    May be considered medically necessary when all stated conditions are met.

    Ab interno stent with cataract surgery: Implantation of 1 or 2 FDA-approved ab interno stents in conjunction with cataract surgery may be considered medically necessary in an individual with mild-to-moderate open-angle glaucoma who is treated with ocular hypotensive medication.1 or 2 stents; mild-to-moderate open-angle glaucoma; treated with ocular hypotensive medication

    The stents must be approved by the U.S. Food and Drug Administration.

    Use of an ab externo aqueous shunt for conditions other than the covered glaucoma indication is considered experimental, investigational, and/or unproven. This includes glaucoma in which intraocular pressure is adequately controlled by medications.

    Use of an ab interno aqueous stent for conditions other than the covered glaucoma indications is considered experimental, investigational, and/or unproven.

    An ab externo aqueous shunt is nonqualifying when used for a condition other than glaucoma with intraocular pressure inadequately controlled by medical therapy. Use is also nonqualifying when medication adequately controls intraocular pressure; these uses are considered experimental, investigational, and/or unproven.

    An ab interno aqueous stent is nonqualifying when used outside the specified covered indications: glaucoma with intraocular pressure inadequately controlled by medical therapy, or implantation of 1 or 2 FDA-approved stents with cataract surgery for treated mild-to-moderate open-angle glaucoma. Other uses are considered experimental, investigational, and/or unproven.

    Procedure, Device, and Supply Codes

    FDA Product Codesmixed
    OGOFDA product code
    KYFFDA product code
    CPT CodesCPT
    66179
    66180
    66183
    66184
    66185
    66989
    66991
    66999
    0253T
    0449T
    1–10 of 13
    1/2
    HCPCS CodesHCPCS
    C1783
    L8612

    Coverage, Documentation, and Billing Guidance

    Documentation Required

    Verify Policy and Benefit Contract

    Review the applicable HealthSpring Medical Policy together with the member’s benefit contract or Summary Plan Description before making a coverage determination. The benefit document governs defined coverage and non-coverage, exclusions, and limitations such as dollar or duration caps.

    Denial Risk

    Nonqualifying Ab Externo Use

    Do not treat ab externo aqueous shunt insertion as covered when the use is outside the policy’s covered indication. Such use is considered experimental, investigational, and/or unproven.

    • Covered consideration requires an FDA-approved ab externo shunt for glaucoma when medical therapy has failed to adequately control intraocular pressure.
    • Use for other conditions, or when intraocular pressure is adequately controlled by medication, is nonqualifying.

    Clinical Background

    Glaucoma surgery is intended to reduce intraocular pressure when the target pressure cannot be reached with medications. Aqueous shunts and stents provide alternative surgical approaches for selected individuals with inadequately controlled glaucoma, including some patients undergoing cataract surgery who have mild-to-moderate open-angle glaucoma.

    Ab externo procedures place a shunt through an external conjunctival and scleral flap. Ab interno procedures use a small corneal incision and access the anterior chamber; these minimally invasive glaucoma surgery approaches involve smaller incisions and less manipulation of the sclera and conjunctiva than traditional techniques. Shunts and stents generally reduce intraocular pressure to the mid-teens and may be inadequate when a substantially lower target pressure is needed.

    Clinical and Technical Definitions

    Moderate glaucoma
    Structural findingsDefinite optic disc, retinal nerve fiber layer (RNFL), or macular imaging abnormalities consistent with glaucoma.
    Visual-field findingsVisual field abnormalities in one hemifield that are not within 5 degrees of fixation.
    Testing methodFindings are assessed with standard automated perimetry (SAP).
    Mild glaucoma
    Structural findingsDefinite optic disc, retinal nerve fiber layer (RNFL), or macular imaging abnormalities consistent with glaucoma.
    Visual-field findingsThe visual field is normal.
    Testing method
    Policy Summary
    PayerHealthSpring
    PolicyAqueous Shunts and Stents for Glaucoma
    Policy CodePolicy SUR713.034
    Change TypeNew policy
    Effective DateMay 7, 2026
    Next Review DateN/A
    Key ActionReview the written Medical Policy coverage position together with the member's benefit contract or Summary Plan Description before determining coverage.
    SourceLink
    On This Page
    Medical Necessity and Covered IndicationsProcedure, Device, and Supply CodesCoverage, Documentation, and Billing GuidanceClinical BackgroundClinical and Technical Definitions
    Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma and visual field abnormalities in one hemifield that are not within 5 degrees of fixation on standard automated perimetry.
    One hemifield; not within 5 degrees of fixation on SAP
  1. Medication treatment: The individual is treated with ocular hypotensive medication.Ocular hypotensive medication
  2. Denial Risk

    Nonqualifying Ab Interno Use

    Do not treat ab interno aqueous stent implantation as covered when the use is outside the policy’s covered indications. Such use is considered experimental, investigational, and/or unproven.

    • Covered consideration includes an FDA-approved ab interno stent for glaucoma when medical therapy has failed to adequately control intraocular pressure.
    • One or two FDA-approved ab interno stents used with cataract surgery may be considered medically necessary for mild-to-moderate open-angle glaucoma treated with ocular hypotensive medication.
    • All other conditions or uses are nonqualifying.
    Note

    Target Pressure Below Device Capability

    Set expectations when a very low intraocular pressure target is needed to limit glaucoma damage. Aqueous shunts and stents are only able to reduce intraocular pressure to the mid-teens and may be inadequate for that clinical objective.

    • Document the clinical rationale and consider whether the device can achieve the required target pressure.
    Billing Rule

    Do Not Determine Coverage From Codes Alone

    Do not determine member benefit coverage or provider reimbursement from procedure, service, supply, or device codes alone. Use the written Medical Policy coverage position and review the member’s benefit contract or Summary Plan Description.

    • Codes listed in the policy do not independently establish coverage or reimbursement.
    • Applicable codes include CPT 66179, 66180, 66183, 66184, 66185, 66989, 66991, 66999, 0253T, 0449T, 0450T, 0474T, and 0671T; and HCPCS C1783 and L8612.
    Denial Risk

    Ab Externo Use Outside Covered Indication

    For current claims, ab externo aqueous shunt use outside the covered indication must be treated as experimental, investigational, and/or unproven. Do not submit or represent nonqualifying use as covered solely because an applicable procedure code is available.

    • Verify that the patient has glaucoma, medical therapy has failed to adequately control intraocular pressure, and the shunt is FDA-approved.
    • Use when intraocular pressure is adequately controlled by medication or for other conditions is outside the covered indication.
    Denial Risk

    Ab Interno Use Outside Covered Indication

    For current claims, ab interno stent use outside the covered indication must be treated as experimental, investigational, and/or unproven. Do not submit or represent nonqualifying use as covered solely because an applicable procedure code is available.

    • Verify the applicable covered pathway: FDA-approved stent for glaucoma after inadequate control with medical therapy, or one or two FDA-approved stents with cataract surgery for mild-to-moderate open-angle glaucoma treated with ocular hypotensive medication.
    • Use for all other conditions is outside the covered indication.
    The visual field is assessed with standard automated perimetry.
    Severe glaucoma
    Structural findingsDefinite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma.
    Visual-field findingsVisual field abnormalities are present in both hemifields and/or there is loss within 5 degrees of fixation in at least one hemifield.
    Testing methodFindings are assessed with standard automated perimetry (SAP).
    Indeterminate glaucoma
    Structural findingsDefinite optic disc or RNFL abnormalities consistent with glaucoma.
    Testing limitationThe patient cannot perform visual-field testing, the results are unreliable or uninterpretable, or visual fields were not performed.
    Severity determinationGlaucoma severity cannot be established from usable visual-field results.
    Ab externo
    ApproachA surgical approach for inserting a shunt or stent through an external flap.
    Conjunctival accessThe device is inserted through an external conjunctival flap.
    Scleral accessThe device is inserted through an external scleral flap.
    Ab interno
    ApproachA minimally invasive approach for device insertion.
    IncisionThe device is inserted through a small incision in the cornea.
    Insertion routeThe device is inserted through the anterior chamber of the eye.
    Minimally invasive glaucoma surgery (MIGS)
    Surgical categoryMinimally invasive glaucoma surgery uses microscopic-sized equipment and smaller incisions.
    Tissue manipulationMIGS involves less surgical manipulation of the sclera and conjunctiva than other surgical techniques.
    Examples of categoriesCategories include miniaturized trabeculectomy, trabecular bypass, milder laser photocoagulation, and totally internal or suprachoroidal stents.
    Refractory or intractable glaucoma
    ConditionGlaucoma is inadequately controlled despite treatment.
    Medical therapyInadequate control persists despite medical therapy.
    Prior surgeryInadequate control may persist despite prior conventional surgical treatment.
    NCT
    AbbreviationNCT
    MeaningNational clinical trial.
    Document usageNCT appears with clinical trial entries, such as NCT01444040 and NCT01461278.
    a
    Notationa
    MeaningDenotes an industry-sponsored or co-sponsored trial.
    Document usageThe notation appears alongside clinical trial identifiers in the trial list.